Seroatlas · Human Serome Atlas

DYNLL2

Dynein light chain 2, cytoplasmic

Also known as: Dlc2, DNCL1B, DYL2_HUMAN, MGC17810, RSPH22

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q96FJ2
Gene: DYNLL2
Ensembl: ENSG00000264364
Chromosome: 17
Canonical length: 89 aa
Protein class: Predicted intracellular proteins
Subcellular location: Nucleoplasm,Cytosol,Mid piece,Principal piece
Quaternary structure: Homodimer

OverviewNCBI Gene

Predicted to enable dynein intermediate chain binding activity. Predicted to be involved in microtubule-based process. Located in 9+0 non-motile cilium and centrosome. Is active in glutamatergic synapse and postsynapse. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

89 residues, UniProt reviewed canonical sequence.

>Q96FJ2|DYNLL2
     1  MSDRKAVIKN ADMSEDMQQD AVDCATQAME KYNIEKDIAA YIKKEFDKKY NPTWHCIVGR
    61  NFGSYVTHET KHFIYFYLGQ VAILLFKSG

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against DYNLL2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.33
Highest tissue expression: 107 nTPM

Expression across tissuesHPA

Tissue

skeletal muscle: 107 nTPM
midbrain: 86 nTPM
basal ganglia: 78 nTPM
cerebral cortex: 75 nTPM
hypothalamus: 71 nTPM
cerebellum: 69 nTPM

Single-cell type

late spermatids: 1,192 nCPM
early spermatids: 523 nCPM
platelets: 210 nCPM
hepatocytes: 121 nCPM
cytotrophoblasts: 121 nCPM
late primary spermatocytes: 117 nCPM

Immune cell

basophil: 1.1 nTPM
non-classical monocyte: 0.9 nTPM
naive CD8 T-cell: 0.8 nTPM
MAIT T-cell: 0.7 nTPM
gdT-cell: 0.6 nTPM
memory CD8 T-cell: 0.6 nTPM

Brain region

midbrain: 136 nTPM
thalamus: 131 nTPM
spinal cord: 121 nTPM
basal ganglia: 120 nTPM
medulla oblongata: 120 nTPM
pons: 119 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about DYNLL2.

Disease | ImmuneIEDB

Conditions an epitope on DYNLL2 was assayed in.

onchocerciasis B cell

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.67
gnomAD pLI: 0.74
gnomAD missense Z: 2.01
DepMap mean gene effect: 0.06
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 7% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

microtubule-based process

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of DYNLL2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads DYNLL2 as an antibody target. Whether an autoantibody or antibody against DYNLL2 could matter depends on whether native DYNLL2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

DYNLL2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label DYNLL2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...